Entera Bio (STU:5DT) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:5DT Entera Bio Ltd STU:5DT
33 GF Score
Price €1.41
GF Value €0.21
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Entera Bio Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

STU:5DT
33GF Score
Entera Bio Ltd STU:5DT
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Entera Bio (STU:5DT) Overvalued in 2026?

Based on GuruFocus' analysis, Entera Bio stock appears to be overvalued. The current stock price of €1.41 is trading 571.4% above its estimated GF Value™ of €0.21. GuruFocus considers Entera Bio to be Significantly Overvalued.

Key valuation signals for STU:5DT:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €0.21 vs. price of €1.41 (571.4% above fair value)
  • GF Score™: 33/100 with 2 warning signs

No single metric tells the full story. See the STU:5DT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Entera Bio Business Description

Other Exchanges ENTX:USA
Address Kiryat Hadassah, Minrav Building - Fifth Floor, Hadassah Bio Park, Jerusalem, ISR, 9112002
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
33GF Score

Get the complete analysis for STU:5DT

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.41
Price
€0.21
GF Value